» Authors » Joseph F Costello

Joseph F Costello

Explore the profile of Joseph F Costello including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 149
Citations 15146
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Appin C, Hong C, Suwala A, Hilz S, Mathur R, Solomon D, et al.
Neuro Oncol . 2023 Dec; 26(4):640-652. PMID: 38141254
Background: The TERT promoter mutation (TPM) is acquired in most IDH-wildtype glioblastomas (GBM) and IDH-mutant oligodendrogliomas (OD) enabling tumor cell immortality. Previous studies on TPM clonality show conflicting results. This...
12.
Hadad S, Gupta R, Oberheim Bush N, Taylor J, Villanueva-Meyer J, Young J, et al.
Acta Neuropathol . 2023 Dec; 147(1):3. PMID: 38079020
Glioblastoma is a clinically and molecularly heterogeneous disease, and new predictive biomarkers are needed to identify those patients most likely to respond to specific treatments. Through prospective genomic profiling of...
13.
Nejo T, Wang L, Leung K, Wang A, Lakshmanachetty S, Gallus M, et al.
bioRxiv . 2023 Nov; PMID: 37961484
Background: Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter-and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative...
14.
Kwok D, Stevers N, Nejo T, Chen L, Etxeberria I, Jung J, et al.
bioRxiv . 2023 Oct; PMID: 37904942
T-cell-mediated immunotherapies are limited by the extent to which cancer-specific antigens are homogenously expressed throughout a tumor. We reasoned that recurrent splicing aberrations in cancer represent a potential source of...
15.
Schupp P, Shelton S, Brody D, Eliscu R, Johnson B, Mazor T, et al.
bioRxiv . 2023 Aug; PMID: 37645893
Tumors may contain billions of cells including distinct malignant clones and nonmalignant cell types. Clarifying the evolutionary histories, prevalence, and defining molecular features of these cells is essential for improving...
16.
Williams E, Ravindranathan A, Gupta R, Stevers N, Suwala A, Hong C, et al.
Neuro Oncol . 2023 Jul; 25(12):2221-2236. PMID: 37436963
Background: Schwannomas are common peripheral nerve sheath tumors that can cause severe morbidity given their stereotypic intracranial and paraspinal locations. Similar to many solid tumors, schwannomas and other nerve sheath...
17.
Minami N, Hong D, Taglang C, Batsios G, Gillespie A, Viswanath P, et al.
Sci Rep . 2023 Mar; 13(1):5190. PMID: 36997627
TERT promoter mutations are a hallmark of glioblastoma (GBM). Accordingly, TERT and GABPB1, a subunit of the upstream mutant TERT promoter transcription factor GABP, are being considered as promising therapeutic...
18.
Jain S, Rick J, Joshi R, Beniwal A, Spatz J, Gill S, et al.
J Clin Invest . 2023 Mar; 133(5). PMID: 36856115
Cancer-associated fibroblasts (CAFs) were presumed absent in glioblastoma given the lack of brain fibroblasts. Serial trypsinization of glioblastoma specimens yielded cells with CAF morphology and single-cell transcriptomic profiles based on...
19.
Carney S, Banerjee K, Mujeeb A, Zhu B, Haase S, Varela M, et al.
Clin Cancer Res . 2023 Jan; 29(9):1763-1782. PMID: 36692427
Purpose: Mutant isocitrate dehydrogenase 1 (mIDH1) alters the epigenetic regulation of chromatin, leading to a hypermethylation phenotype in adult glioma. This work focuses on identifying gene targets epigenetically dysregulated by...
20.
Miller J, Gonzalez Castro L, McBrayer S, Weller M, Cloughesy T, Portnow J, et al.
Neuro Oncol . 2022 Oct; 25(1):4-25. PMID: 36239925
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent...